Evidence map›Paper›PMID 42651150›Full record

ArticleBrain sciences2026

Plasma Biomarkers of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Karmen Aslankurt, Hanna Schenck, Sander M J van Kuijk, Govert Hoogland, Inger de Ridder, Onno Teernstra, Jim Dings, Marcel Aries, Michael Veldeman, Hans Vink and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karmen AslankurtMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0009-0002-7840-6353
Hanna SchenckMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Sander M J van KuijkDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, 6202 AZ Maastricht, The Netherlands.
Govert HooglandMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Inger de RidderMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Onno TeernstraMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Jim DingsMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Marcel AriesMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Michael VeldemanDepartment of Neurosurgery, RWTH Uniklinikum Aachen, 52074 Aachen, Germany.ORCID 0000-0003-3648-6842
Hans VinkGlycoCalyx Research Institute, Alpine, UT 84004, USA.
Yasin TemelMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.
Rick van LanenMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0002-6557-9127
Roel HaerenMental Health and Neuroscience Research Institute, Maastricht University, 6200 MD Maastricht, The Netherlands.ORCID 0000-0003-1640-5013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening neurovascular emergency. Among survivors, the most dreaded complication is delayed cerebral ischemia (DCI), affecting approximately one third of aSAH patients. Several mechanisms contributing to DCI have been described, yet the pathophysiology remains unclear. Disruption of the endothelial glycocalyx plays a key role in these pathomechanisms and is therefore of particular interest. This study aimed to explore changes in plasma glycocalyx breakdown products following aSAH and in relation to the development of DCI.

methodsIn this prospective study, plasma samples were collected during a two-week follow-up period after aSAH diagnosis. Baseline plasma samples were collected within 72 h after ictus, followed by two additional samples in the first week and three samples in the second week. In patients who developed DCI, additional daily samples were obtained. DCI was defined using its clinical definition. Glycocalyx breakdown products syndecan-1 and hyaluronan concentrations were measured using enzyme-linked immunosorbent assays (ELISA) kits.

resultsTwenty-nine aSAH patients were included, of whom six developed DCI. Overall, median syndecan-1 concentrations increased significantly from baseline (33.72 ng/mL, IQR 23.29-42.55 ng/mL) to the day 14 measurements (44.83 ng/mL, IQR 32.52-62.68) (

conclusionsThe results from this explorative study indicate that aSAH is associated with glycocalyx breakdown. While hyaluronan levels were high in the acute phase and decreased thereafter, syndecan-1 levels increased during the first two weeks following aSAH in DCI patients. For syndecan-1, this change was more pronounced in DCI patients. Our findings suggest an involvement of glycocalyx breakdown in the pathophysiology of DCI. This study requires validation in larger cohorts to strengthen our results, and establishes the potential of glycocalyx breakdown products as biomarkers for DCI.

Indexed as

aneurysmal subarachnoid hemorrhagebiomarkerdelayed cerebral ischemiaglycocalyxhyaluronansyndecan-1

Identifiers

PMID42651150
PMCPMC13510835

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.